Helen M. Colhoun
Western General Hospital
EndocrinologyCardiologyType 2 diabetesDiabetes mellitusMedicine
What is this?
Publications 263
#1E. Whittaker (Edin.: University of Edinburgh)
#2Stephanie H. ReadH-Index: 7
Last. Sarah H. WildH-Index: 69
view all 8 authors...
#1Marco Colombo (Edin.: University of Edinburgh)H-Index: 9
#4Finlay MacKenzieH-Index: 1
Last. Helen M. Colhoun (Edin.: University of Edinburgh)H-Index: 50
view all 12 authors...
Aims/hypothesis The aim of this study was to provide data from a contemporary population-representative cohort on rates and predictors of renal decline in type 1 diabetes.
1 CitationsSource
#1Peter McMeekin (Glas.: University of Glasgow)H-Index: 13
#2C. Geue (Glas.: University of Glasgow)
Last. Olivia Wu (Glas.: University of Glasgow)H-Index: 21
view all 9 authors...
Aim To compare costs for three groups of people with type 2 diabetes, those at high risk of future cardiovascular disease, those without cardiovascular disease and those with established cardiovascular disease, and to also compare costs incurred by people with type 2 diabetes with an incident cardiovascular disease event with those who remain incident event‐free over a 3‐year period. Methods Data about people with type 2 diabetes in Scotland were obtained from the Scottish Care Information Diabe...
#1Helen M. Colhoun (Western General Hospital)H-Index: 50
#2Lawrence A. Leiter (U of T: University of Toronto)H-Index: 36
Last. Rita Samuel (Regeneron)H-Index: 4
view all 11 authors...
Background Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk. Non-HDL-C and apolipoprotein B (ApoB) are the preferred therapeutic targets for mixed dyslipidemia. Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that effectively reduces low-density lipoprotein cholesterol (LDL-C),...
1 CitationsSource
#1John McKnight (Edin.: University of Edinburgh)H-Index: 24
#2A. Ochs (Edin.: University of Edinburgh)
Last. Helen M. Colhoun (Edin.: University of Edinburgh)H-Index: 50
view all 11 authors...
#1R. A. S. Campbell (Edin.: University of Edinburgh)
#2Helen M. Colhoun (Western General Hospital)H-Index: 50
Last. Sarah H. Wild (Edin.: University of Edinburgh)H-Index: 69
view all 7 authors...
#1Lucija Klarić (Edin.: University of Edinburgh)H-Index: 9
#2Yakov A. Tsepilov (NSU: Novosibirsk State University)H-Index: 5
Last. Stuart McGurnaghan (Edin.: University of Edinburgh)H-Index: 6
view all 53 authors...
Effector functions of immunoglobulin G (IgG) are regulated by the composition of a glycan moiety, thus affecting activity of the immune system. Aberrant glycosylation of IgG has been observed in many diseases, but little is understood about the underlying mechanisms. We performed a genome-wide association study of IgG N-glycosylation (N = 8090) and, using a data-driven network approach, suggested how associated loci form a functional network. We confirmed in vitro that knockdown of IKZF1 decreas...
1 CitationsSource
#1Anita JeyamH-Index: 1
#2Stuart McGurnaghanH-Index: 6
Last. Helen M. ColhounH-Index: 50
view all 8 authors...
OBJECTIVE To assess the contemporaneous prevalence of diabetic peripheral neuropathy (DPN) in people with type 1 diabetes (T1D) in Scotland and study its cross-sectional association with risk factors and other diabetic complications. RESEARCH DESIGN AND METHODS We analyzed data from a large representative sample of adults with T1D (N = 5,558). We assessed the presence of symptomatic neuropathy using the dichotomized (≥4) Michigan Screening Instrument Patient Questionnaire score. Logistic regress...
1 CitationsSource
#1Marco Colombo (Edin.: University of Edinburgh)H-Index: 9
#3Stuart McGurnaghan (Western General Hospital)H-Index: 6
Last. Helen M. Colhoun (Western General Hospital)H-Index: 50
view all 14 authors...
Aims/hypothesis We examined whether candidate biomarkers in serum or urine can improve the prediction of renal disease progression in type 1 diabetes beyond prior eGFR, comparing their performance with urinary albumin/creatinine ratio (ACR).
#1Hertzel C. Gerstein (HHS: Hamilton Health Sciences)H-Index: 93
#2Robert G. Hart (Population Health Research Institute)H-Index: 83
Last. T. Temelkova-KurktschievH-Index: 20
view all 29 authors...
Summary Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial. Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at 371 sites in 24 countries. Men and women (aged ≥50 years) with established or newly detected type 2 diabetes whose HbA1c w...
1 CitationsSource